Arrayjet strikes deal worth USD $250,000 to support life sciences research
Arrayjet, the Midlothian-based microarray instrumentation company, has secured a major contract with The New York Bioscience Cluster, one of America’s premier medical education and biomedical research facilities.
The firm’s Marathon Argus high throughput bio printer will support the Bronx-based Bioscience Cluster’s research into diseases and disorders related to immunology cancer, diabetes, liver function, and a raft of other areas where gene expression in cells are prevalent, as part of a new contract worth around USD $250,000.
Arrayjet says microarray sampling is at the core of this research, as is the development to significantly reduce the margin of error in printed array slides.
The firm says its optical inspection and automated image analysis system has added a significant step change in identifying where any errors might exist and eradicate them – giving the New York Bioscience Cluster a guarantee that each printed array slide delivers a continuously consistent product quality, which is not only financially cost effective in the long term, but improves the quality of arrays, increases yields and throughput which, in turn, improves productivity.
It facilitates the automatic detection of defects in microarray ‘spots’ as well as customising their data report and quality control threshold criteria.
The New York Bioscience Cluster is also supported through Arrayjet Advance – the outsourced customised microarray printing services which Arrayjet launched in 2011.
This allows the facility to access application support through the wealth of scientific expertise at Arrayjet HQ.
Arrayjet is supported by investment from the Archangels business angel syndicate and Scottish Enterprise.